Chenodeoxycholic Acid from Japan: Sourcing Guide for Rare Disease Clinics

What Is Chenodeoxycholic Acid and Why Is Japan a Key Source?

Chenodeoxycholic acid (CDCA) is a bile acid used therapeutically in two distinct clinical contexts. In Japan, it has long been approved as a standard treatment for cholesterol gallstones. In the European Union and United Kingdom, it holds orphan drug designation for cerebrotendinous xanthomatosis (CTX)—a rare inherited disorder of bile acid synthesis that causes progressive neurological damage, tendon xanthomas, and premature cataracts if untreated.

This regulatory asymmetry is clinically significant. CTX is caused by a deficiency in the enzyme sterol 27-hydroxylase (CYP27A1), leading to accumulation of cholestanol and cholesterol. Oral chenodeoxycholic acid replacement therapy suppresses the abnormal bile acid synthesis pathway and is the established treatment of choice. However, in markets where CDCA is not locally registered or is in limited supply, Japanese-manufactured product represents a proven, GMP-compliant alternative accessible through pharmaceutical importation frameworks.

Regulatory Status by Market

Clinical Use in Cerebrotendinous Xanthomatosis

CTX is a rare autosomal recessive condition. Early diagnosis and treatment with chenodeoxycholic acid can halt or significantly slow disease progression. Treatment typically involves oral CDCA at doses of 250 mg three times daily in adults, normalising bile acid synthesis and reducing cholestanol accumulation over time.

Because CTX is rare and often diagnosed late, specialist metabolic disease centres and neurology departments frequently need to source CDCA through non-standard procurement pathways. Japanese-manufactured CDCA—produced under PIC/S-recognised GMP standards—is a clinically appropriate option for these centres.

Documentation Available for Regulatory Compliance

When sourcing chenodeoxycholic acid from Japan for importation under an unlicensed or named patient framework, the following documentation is typically available:

• Certificate of Origin (CoO): Confirming Japanese manufacture
• Certificate of Analysis (CoA): Batch-specific quality data
• Patient Information Leaflet (PIL): Japanese language; translation summary available
• GDP compliance records: Documenting storage and transport conditions
• Manufacturer GMP certificate: Confirming PIC/S-compliant manufacturing

Practical Sourcing Information

Chenodeoxycholic acid is available in Japan in oral tablet and capsule formulations. Standard packaging and strength information can be confirmed via the J-Lex database (db.tasakipharma.com) by searching for “chenodeoxycholic acid” or the active ingredient name.

For procurement teams initiating first-time importation, it is important to factor in the notification lead time required by the destination country’s regulatory authority (e.g., 28 days for MHRA in the UK) when planning supply timelines.

How TASAKI PHARMA Can Help

TASAKI PHARMA is a Taiwan-based pharmaceutical trading company with GDP and PIC/S GMP-compliant operations, experienced in supplying Japan-origin pharmaceuticals to rare disease centres in the UK, Australia, Singapore, and Hong Kong.

• Chenodeoxycholic acid and other Japan-approved rare disease products available via J-Lex (db.tasakipharma.com)
• CoO, CoA, and PIL documentation upon request
• GDP-compliant logistics with temperature-controlled packaging and data loggers where required
• Ex Works pricing in USD, EUR, or JPY

To enquire about chenodeoxycholic acid availability and pricing, visit tasakipharma.com.